Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+1.94%
-0.02%
+2.10%
-0.39%
+0.50%
ACN
Accenture
$286.96
Chart
$314.47 (-8.75%)
$282.58 (+1.55%)
$341.84 (-16.05%)
$326.2 (-12.03%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+1.94%
-0.02%
+2.10%
-0.39%
+0.50%
ACN
Accenture
Current Price
$286.96
Buy
Login to view Accenture (ACN) recommendation from the last 90 days from financial news and social media.
Chart
$314.47 (-8.75%)
$282.58 (+1.55%)
$341.84 (-16.05%)
$326.2 (-12.03%)
ACN Latest Analysis
Accenture Expands In Malaysia With Aristal Purchase. ) said Tuesday it has purchased The purchase brings Aristal'.s experience guiding banks through major core platform upgrades in Malaysia Indonesia Singapore and Thailand according to a press release.Aristal'.s team of 30 consultants will join Accenture'.s Financial Services practice in Malaysia enhancing its ability to modernize banks'. core systems optimize operations and support merger integrations.
Tue Jul 22, 2025
From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits. News CommentaryIssued on behalf of Avant Technologies Inc. News Commentary – The AI revolution in healthcare is fully underway with the potential to but there'.s still more to come. Healthcare startups are already figuring out how to to multiply their patients and chase profits to the benefit of investors. More Americans than ever are as the is becoming the norm among medical professionals. Now the developers
Tue Jul 22, 2025
Accenture CEO sweet sells $635k in shares.
Mon Jul 14, 2025
Accenture Enters Oversold Territory. The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks according to a proprietary formula designed to identify those stocks that combine two important characteristics &mdash. strong fundamentals and a valuation that looks inexpensive.
Mon Jul 14, 2025
Market Whales and Their Recent Bets on ACN Options. Deep-pocketed investors have adopted a bearish approach towards Accenture (NYSE:) and it'.s something market players shouldn'.t ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown but such a substantial move in ACN usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga'.s optio
Thu Jul 10, 2025
$1000 Invested In Accenture 20 Years Ago Would Be Worth This Much Today. Accenture (NYSE:) has outperformed the market over the past 20 years by 4.64% on an annualized basis producing an average annual return of 13.11%. Currently Accenture has a market capitalization of $181.44 billion.
Thu Jul 10, 2025
Healthcares $110B AI Surge Is Picking Up Speed--and Its Just the Beginning. News CommentaryIssued on behalf of Avant Technologies Inc. in Nature introduced an ".AI Affinity Score". to measure patient comfort with AI in clinical settings—showing that education level and region heavily influence acceptance. The findings suggest that personalizing AI integration based on patient attitudes can enhance care quality and satisfaction. That kind of insight is already guiding investor attention to
Tue Jul 8, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings